Skip to main content

Table 2 Effect of liraglutide versus placebo on systolic function at each stress level

From: Effects of the glucagon-like peptide-1 receptor agonist liraglutide on systolic function in patients with coronary artery disease and type 2 diabetes: a randomized double-blind placebo-controlled crossover study

 

Before liraglutide

After liraglutide

Before placebo

After placebo

N

Treatment effect

Difference (95 % CI)

p value

Baseline

12 weeks

Baseline

12 weeks

Liraglutide

Placebo

LVEF, %

 Rest

59.46 (7.44)

60.13 (9.07)

59.27 (7.92)

59.41 (7.92)

30

0.67 (6.30)

0.13 (4.95)

0.54 (−2.38 to 3.45)

0.710

 Low stress

70.73 (9.58)

71.03 (10.7)

71.31 (9.51)

71.44 (8.43)

29

0.28 (6.27)

0.25 (6.56)

0.03 (−3.25 to 3.32)

0.984

 Peak stress

75.72 (9.52)

76.92 (9.14)

76.26 (8.72)

76.02 (8.12)

24

0.87 (6.91)

−0.25 (7.26)

1.12 (−3.45 to 5.69)

0.618

 Recovery

60.65 (10.38)

64.91 (10.44)

62.52 (10.20)

62.84 (9.88)

29

4.25 (7.13)

0.20 (8.97)

4.06 (−0.81 to 8.93)

0.099

WMSI

 Rest

1.088 (0.155)

1.084 (0.163)

1.088 (0.144)

1.075 (0.140)

30

−0.003 (0.065)

−0.013 (0.055)

0.009 (−0.018 to 0.037)

0.492

 Low stress

1.078 (0.202)

1.077 (0.171)

1.059 (0.143)

1.048 (0.128)

29

0.004 (0.097)

−0.011 (0.056)

0.007 (−0.035 to 0.049)

0.725

 Peak stress

1.079 (0.235)

1.052 (0.160)

1.058 (0.149)

1.060 (0.213)

24

−0.03 (0.10)

0.01 (0.08)

−0.038 (−0.112 to 0.035)

0.292

 Recovery

1.090 (0.198)

1.096 (0.212)

1.081 (0.157)

1.090 (0.192)

29

0.007 (0.07)

0.006 (0.11)

0.001 (−0.045 to 0.047)

0.963

GLS

 Rest

16.26 (2.60)

15.53 (2.72)

16.44 (3.07)

16.34 (2.90)

30

−0.73 (1.87)

−0.10 (1.87)

−0.63 (−0.42 to 1.67)

0.231

GLSR, s−1

 Rest

0.90 (0.18)

0.91 (0.18)

0.86 (0.17)

0.88 (0.2)18

30

0.01 (0.15)

0.02 (0.14)

−0.01 (−0.05 to 0.08)

0.713

  1. Data are expressed as the mean (SD)
  2. N is the number of subjects for each treatment phase with valid measurements in each stress level, GLS global longitudinal strain, GLSR global longitudinal strain rate, WMSI wall motion score index, LVEF left ventricular ejection fraction